| Symbol | STEX |
|---|---|
| Name | BIOSIG TECHNOLOGIES, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Address | 54 WILTON ROAD,2ND FLOOR, WESTPORT, Connecticut, 06880, United States |
| Telephone | +1 203 409-5444 |
| Fax | — |
| — | |
| Website | https://www.biosig.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001530766 |
| Description | BioSig Technologies is an advanced medical technology company bringing never-before-seen insights to the treatment of cardiovascular arrhythmias. Through collaboration with physicians, experts, and healthcare leaders across the field of electrophysiology (EP), BioSig is committed to addressing healthcares biggest priorities-saving time, saving costs, and saving lives. The Companys first product, the PURE EP System, an FDA 510(k) cleared non-invasive class II device, provides superior, real-time signal visualization allowing physicians to perform insight-based, highly targeted cardiac ablation procedures with increased procedural efficiency and efficacy. The global EP market is projected to reach $16B in 2028 with an 11.2% growth rate. Additional info from NASDAQ: |
Streamex Corp. Announces First Independent Reserve Attestation by EisnerAmper for GLDY
Read moreStreamex Corp. Brings Yield-Bearing Gold (GLDY) to Traditional Brokerage Accounts Through Collaboration with Siebert Financial and tZERO
Read moreDirector Lekstrom Morgan Lee 🟢 acquired 50.0K shares of Streamex Corp. (STEX) at $1.01 Transaction Date: Jun 12, 2026 | Filing ID: 028646
Read moreDirector Williams Mitchell Young 🔴 sold 23.8K shares of Streamex Corp. (STEX) at $1.05 Transaction Date: Jun 01, 2026 | Filing ID: 026956
Read moreNew Form 4/A - Streamex Corp. <b>Filed:</b> 2026-05-28 <b>AccNo:</b> 0001493152-26-025696 <b>Size:</b> 6 KB
Read moreNew Form 4/A - Streamex Corp. <b>Filed:</b> 2026-05-28 <b>AccNo:</b> 0001493152-26-025695 <b>Size:</b> 6 KB
Read moreDirector Lekstrom Morgan Lee 🟢 acquired 34.0K shares of Streamex Corp. (STEX) at $1.47 Transaction Date: May 28, 2026 | Filing ID: 025586
Read moreStreamex Corp. and Orca Announce Launch of 24/7 Decentralized Secondary Liquidity Infrastructure for Tokenized Securities; GLDY the Inaugural Asset
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07659938 | Frontal Gamma Coherence Neurofeedback for Patients With Schizophrenia | Na | Schizophrenia | Not_Yet_Recruiting | 2027-04-01 | 2028-06-01 | ClinicalTrials.gov |
| NCT07476313 | Validation and Usability Study of the SleepView+ Home Sleep Testing System for … | — | Obstructive Sleep Apnea | Enrolling_By_Invitation | 2026-02-15 | 2026-12-15 | ClinicalTrials.gov |
| NCT07110376 | Deep Brain Stimulation Neural Recordings of Varied Stimulation During Sleep in … | Na | Parkinson Disease | Recruiting | 2025-11-22 | 2026-12-31 | ClinicalTrials.gov |
| NCT06531876 | Efficacy of the Dreem 3S Ambulatory Sleep Monitoring Device for the Evaluation … | — | Narcolepsy Type 1 | Completed | 2024-07-01 | 2026-03-01 | ClinicalTrials.gov |
| NCT05503355 | A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in … | Phase1 | AML, Adult | Unknown | 2022-08-17 | 2025-12-01 | ClinicalTrials.gov |
| NCT04964440 | Redo AF Sub Study (of the Pure EP 2.0 Main Study) | — | Atrial Fibrillation Recurrent | Completed | 2021-03-03 | 2022-01-29 | ClinicalTrials.gov |
| NCT04112433 | Novel Cardiac Signal Processing System | — | Cardiac Arrhythmia | Completed | 2019-11-12 | 2022-01-29 | ClinicalTrials.gov |
| NCT02544438 | Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemi… | Phase1 | Acute Myeloid Leukemia | Completed | 2015-09-01 | 2017-09-20 | ClinicalTrials.gov |
| NCT02128477 | Predictive Value of Periodic Repolarization Dynamics in Post-Infarction Patients | — | Myocardial Infarction | Completed | 2010-10-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT01486589 | Cardiac Autonomic Function For Risk Stratification in the Emergency Room | — | Autonomic Nervous System Activity | Completed | 2010-10-01 | — | ClinicalTrials.gov |
| NCT01422057 | Risk Prediction in Type II Diabetics With Ischemic Heart Disease | — | Type-2 Diabetes Mellitus | Unknown | 2010-01-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT01422044 | Risk Prediction in Aortic Stenosis | — | Aortic Stenosis | Completed | 2009-09-01 | 2014-01-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo Neurofeedback | Other | Approved | Schizophrenia | NOT_YET_RECRUITING | NCT07659938 |
| Frontal gamma coherence neurofeedback | Other | Approved | Schizophrenia | NOT_YET_RECRUITING | NCT07659938 |
| Astarabine (BST-236) | Other | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT02544438 |
| Astarabine (BST-236) | Other | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT02544438 |
| Pure-EP | Other | Preclinical | Atrial Fibrillation Recurrent | COMPLETED | NCT04964440 |
| PURE EP 2 | Other | Preclinical | Cardiac Arrhythmia | COMPLETED | NCT04112433 |
| venetoclax | Other | Phase PHASE1 | AML, Adult | UNKNOWN | NCT05503355 |
| BST-236 | Other | Phase PHASE1 | AML, Adult | UNKNOWN | NCT05503355 |
| venetoclax | Other | Phase PHASE1 | AML, Adult | UNKNOWN | NCT05503355 |
| BST-236 | Other | Phase PHASE1 | AML, Adult | UNKNOWN | NCT05503355 |
| Nighttime Deep Brain Stimulation with Varying Amplitude Settings | Other | Approved | Parkinson Disease | RECRUITING | NCT07110376 |
| Nighttime Deep Brain Stimulation with Varying Amplitude Settings | Other | Approved | Parkinson Disease | RECRUITING | NCT07110376 |
| SleepView+ | Other | Preclinical | Obstructive Sleep Apnea | ENROLLING_BY_INVITATION | NCT07476313 |
| SleepView+ | Other | Preclinical | Obstructive Sleep Apnea | ENROLLING_BY_INVITATION | NCT07476313 |
| Dreem 3S recording | Other | Preclinical | Narcolepsy Type 1 | COMPLETED | NCT06531876 |
| Dreem 3S recording | Other | Preclinical | Narcolepsy Type 1 | COMPLETED | NCT06531876 |
| Dreem 3S recording | Other | Preclinical | Narcolepsy Type 1 | COMPLETED | NCT06531876 |
| Pure-EP | DEVICE | Preclinical | Atrial Fibrillation Recurrent | COMPLETED | NCT04964440 |
| PURE EP 2 | DEVICE | Preclinical | Cardiac Arrhythmia | COMPLETED | NCT04112433 |